179 related articles for article (PubMed ID: 16228237)
1. 11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas.
Tang BN; Levivier M; Heureux M; Wikler D; Massager N; Devriendt D; David P; Dumarey N; Corvilain B; Goldman S
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):169-78. PubMed ID: 16228237
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of combination [
Wang Z; Feng Z; Zhu D; Wang X; Chen J; Zhu Y; Wang H
BMC Endocr Disord; 2024 Feb; 24(1):19. PubMed ID: 38311763
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of coregistered 11C-methionine positron emission tomography/3-T magnetic resonance imaging at the follow-up of acromegaly.
Rodriguez-Barcelo S; Gutierrez-Cardo A; Dominguez-Paez M; Medina-Imbroda J; Romero-Moreno L; Arraez-Sanchez M
World Neurosurg; 2014; 82(3-4):468-73. PubMed ID: 24239736
[TBL] [Abstract][Full Text] [Related]
4. Utility of 11C-Methionine and 18F-FDG PET/CT in Patients With Functioning Pituitary Adenomas.
Feng Z; He D; Mao Z; Wang Z; Zhu Y; Zhang X; Wang H
Clin Nucl Med; 2016 Mar; 41(3):e130-4. PubMed ID: 26646998
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of composite methionine-positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma.
Ikeda H; Abe T; Watanabe K
J Neurosurg; 2010 Apr; 112(4):750-5. PubMed ID: 19698042
[TBL] [Abstract][Full Text] [Related]
6. Real-world experience with 11C-methionine positron emission tomography in the management of acromegaly.
Haberbosch L; MacFarlane J; Koulouri O; Gillett D; Powlson AS; Oddy S; Halsall DJ; Huynh KA; Jones J; Cheow HK; Spranger J; Mai K; Strasburger CJ; Mannion RJ; Gurnell M
Eur J Endocrinol; 2024 Mar; 190(4):307-313. PubMed ID: 38482632
[TBL] [Abstract][Full Text] [Related]
7. The Application of Magnetic Resonance Imaging-Deformed 11C-Methionine-Positron Emission Tomography Images in Stereotactic Radiosurgery.
Jung TY; Jung S; Ryu HS; Kim IY; Jang WY; Moon KS; Lim SH; Kim DY; Kang SR; Min JJ; Bom HS; Kim SK; Kwon SY
Stereotact Funct Neurosurg; 2019; 97(4):217-224. PubMed ID: 31694035
[TBL] [Abstract][Full Text] [Related]
8. Clinical decision-making based on 11C-methionine PET in recurrent Cushing's disease with equivocal MRI findings.
Ishida A; Kaneko K; Minamimoto R; Hotta M; Inoshita N; Takano K; Yamada S
J Neurosurg; 2023 Dec; 139(6):1671-1680. PubMed ID: 37410630
[TBL] [Abstract][Full Text] [Related]
9. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].
Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892
[TBL] [Abstract][Full Text] [Related]
10. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy.
Grosu AL; Weber WA; Riedel E; Jeremic B; Nieder C; Franz M; Gumprecht H; Jaeger R; Schwaiger M; Molls M
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):64-74. PubMed ID: 16111573
[TBL] [Abstract][Full Text] [Related]
11. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?
Tsuyuguchi N; Sunada I; Iwai Y; Yamanaka K; Tanaka K; Takami T; Otsuka Y; Sakamoto S; Ohata K; Goto T; Hara M
J Neurosurg; 2003 May; 98(5):1056-64. PubMed ID: 12744366
[TBL] [Abstract][Full Text] [Related]
12. A comparison between 11C-methionine PET/CT and MIBI SPECT/CT for localization of parathyroid adenomas/hyperplasia.
Hayakawa N; Nakamoto Y; Kurihara K; Yasoda A; Kanamoto N; Miura M; Inagaki N; Togashi K
Nucl Med Commun; 2015 Jan; 36(1):53-9. PubMed ID: 25244350
[TBL] [Abstract][Full Text] [Related]
13. Target definition by C11-methionine-PET for the radiotherapy of brain metastases.
Matsuo M; Miwa K; Shinoda J; Kako N; Nishibori H; Sakurai K; Yano H; Iwama T; Kanematsu M
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):714-22. PubMed ID: 19095373
[TBL] [Abstract][Full Text] [Related]
14. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas.
Minniti G; Traish D; Ashley S; Gonsalves A; Brada M
Clin Endocrinol (Oxf); 2006 May; 64(5):542-8. PubMed ID: 16649974
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
16. Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET.
Otto D; Boerner AR; Hofmann M; Brunkhorst T; Meyer GJ; Petrich T; Scheumann GF; Knapp WH
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1405-12. PubMed ID: 15278308
[TBL] [Abstract][Full Text] [Related]
17. CyberKnife radiosurgery planning of a secreting pituitary adenoma performed with ⁶⁸Ga DOTATATE PET and MRI.
d'Amico A; Stąpór-Fudzińska M; Tarnawski R
Clin Nucl Med; 2014 Dec; 39(12):1043-4. PubMed ID: 25140540
[TBL] [Abstract][Full Text] [Related]
18. Demonstration of high coincidence of pituitary adenoma in patients with ruptured Rathke's cleft cyst: Results of a prospective study.
Ikeda H; Ohhashi G
Clin Neurol Neurosurg; 2015 Dec; 139():144-51. PubMed ID: 26473987
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefit of 11C methionine PET imaging as a planning modality for radiosurgery of previously irradiated recurrent brain metastases.
Momose T; Nariai T; Kawabe T; Inaji M; Tanaka Y; Watanabe S; Maehara T; Oda K; Ishii K; Ishiwata K; Yamamoto M
Clin Nucl Med; 2014 Nov; 39(11):939-43. PubMed ID: 25140562
[TBL] [Abstract][Full Text] [Related]
20. The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours.
Acosta-Gómez MJ; Muros MA; Llamas-Elvira JM; Ramírez A; Ortega S; Sabatel G; Ramos C; de la Riva-Aguilar A
Br J Radiol; 2005 Feb; 78(926):110-5. PubMed ID: 15681321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
